Cara Therapeutics to Announce Third Quarter 2019 Financial Results on November 5, 2019
October 29 2019 - 4:01PM
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company
focused on developing and commercializing new chemical entities
designed to alleviate pruritus by selectively targeting peripheral
kappa opioid receptors, today announced that the Company will host
a conference call and live audio webcast on Tuesday, November 5,
2019, at 4:30 p.m. ET to report third quarter 2019 financial
results and provide a corporate update.
To participate in the conference call, please
dial (855) 445-2816 (domestic) or (484) 756-4300 (international)
and refer to conference ID 9284479. A live webcast of the call can
be accessed under “Events & Presentations” in the News &
Investors section of the Company’s website at
www.CaraTherapeutics.com.
An archived webcast recording will be available
on the Cara website beginning approximately two hours after the
call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pruritus by selectively
targeting peripheral kappa opioid receptors (KORs). Cara is
developing a novel and proprietary class of product candidates, led
by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist
that targets the body's peripheral nervous system, as well as
certain immune cells. In both Phase 3 and Phase 2 trials, KORSUVA
Injection has demonstrated statistically significant reductions in
itch intensity and concomitant improvement in quality of life
measures in hemodialysis patients with moderate-to-severe chronic
kidney disease-associated pruritus (CKD-aP). KORSUVA Injection is
currently being investigated in pivotal Phase 3 trials in
hemodialysis patients with CKD-aP. Oral KORSUVA is in Phase 2
trials for the treatment of pruritus in patients with CKD, atopic
dermatitis and primary biliary cholangitis (PBC).
The FDA has conditionally accepted KORSUVA™ as
the trade name for difelikefalin injection. CR845/difelikefalin is
an investigational drug product and its safety and efficacy have
not been fully evaluated by any regulatory authority.
MEDIA CONTACT: Annie Starr 6 Degrees
973-415-8838 astarr@6degreespr.com
INVESTOR CONTACT: Jane Urheim Stern Investor
Relations, Inc. 212-362-1200 Jane.Urheim@SternIR.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024